ECMED · Project

New Drug Targets and Diagnostic Tools for Treatment-Resistant Epilepsy

healthPrototypeTRL 3Thin data (2/5)

Your brain cells sit in a kind of scaffolding — a mesh of proteins called the extracellular matrix — that controls how signals travel between neurons. When this scaffolding breaks down or changes, it can trigger epileptic seizures. ECMED brought together 11 research teams across Europe to figure out exactly how this scaffolding goes wrong and whether fixing it could prevent or treat epilepsy. They also built new tools, like high-resolution electrode arrays, to study seizures more precisely than before.

By the numbers

50 million

people worldwide affected by epilepsy

30%

of epilepsy patients resistant to current therapies

consortium partners across 9 countries

total project deliverables

The business problem

What needed solving

Over 50 million people worldwide suffer from epilepsy, and 30% of them do not respond to any existing treatment. Current drugs target a narrow set of biological mechanisms, leaving a massive unmet medical need. Companies developing epilepsy therapies and diagnostics need new biological targets and better tools to understand how seizures develop.

The solution

What was built

The project produced 8 deliverables, including a demonstration-level protocol for seizure analysis using high-resolution microelectrode arrays (MEAs). The consortium also mapped how extracellular matrix proteins change during epilepsy development and identified ECM protein mutations linked to epilepsy.

Audience

Who needs this

Pharma companies with neurology drug pipelines seeking new epilepsy targetsMedical device companies developing seizure monitoring and EEG equipmentBiotech firms selling neuroscience research tools and assaysContract research organizations offering preclinical neurology servicesAcademic medical centers running epilepsy clinical trials

Business applications

Who can put this to work

Pharmaceutical & Drug Discovery

enterprise

Target: Pharma companies with neurology pipelines targeting epilepsy or neurodegeneration

If you are a pharma company struggling with the fact that 30% of epilepsy patients don't respond to existing drugs — this project mapped new biological targets in the brain's extracellular matrix that could open entirely new treatment pathways. The consortium identified ECM protein mutations associated with epilepsy and studied how the matrix changes during disease development, giving you validated targets for drug screening campaigns.

Medical Devices & Neurodiagnostics

mid-size

Target: Companies developing EEG equipment or neural monitoring devices

If you are a neurodiagnostic device maker looking to improve seizure detection accuracy — this project developed a protocol for high-resolution microelectrode arrays (MEAs) that enables more precise seizure analysis. With over 50 million epilepsy patients worldwide needing better monitoring, integrating this approach could differentiate your diagnostic platform in a growing market.

Biotech & Research Tools

SME

Target: Biotech companies selling reagents, assays, or research platforms for neuroscience

If you are a research tools supplier serving the neuroscience market — this project generated validated protocols and research methods around extracellular matrix biology in epilepsy, stroke, and neurodegeneration. The consortium's 2 industry partners already contributed diagnostic and research tools, and the published methods from 8 deliverables represent catalog-ready products for academic and pharma customers.

Frequently asked

Quick answers

What would it cost to license or access these research results?

ECMED was funded as a Marie Skłodowska-Curie training network, meaning most outputs are published in open-access scientific literature. Licensing specific protocols like the high-resolution MEA seizure analysis method would require negotiation with University College London or the relevant consortium partner. Costs would depend on exclusivity and field of use.

Can these findings work at industrial scale for drug screening?

The extracellular matrix targets identified by the project provide a biological rationale for drug screening, but the project itself was research-stage. Scaling the MEA-based seizure analysis protocol into a high-throughput screening platform would require additional engineering and validation work.

What is the IP situation — are there patents?

Based on available project data, ECMED was primarily a training network and no specific patent filings are mentioned in the deliverables. IP generated during the project would be governed by the consortium agreement among the 11 partners. Contact the coordinator at University College London for IP availability.

Is this relevant to diseases beyond epilepsy?

Yes. The project explicitly investigated ECM connections to stroke, traumatic brain injury, neurodegeneration, and autism. The EuroSciVoc classification also includes dementia and drug discovery, suggesting the biological insights have broader neurological applications.

How mature is the seizure analysis protocol?

The project delivered a protocol for high-resolution MEA use in seizure analysis, classified as a demonstration deliverable. This suggests it has been validated in a laboratory setting but has not been tested in clinical or commercial environments. Based on available project data, further validation would be needed before clinical deployment.

Are there regulatory considerations for using these results?

Any diagnostic tool or therapeutic derived from this research would need to go through standard medical device or pharmaceutical regulatory approval. The MEA protocol is a research tool at this stage and would require clinical validation before regulatory submission.

Who were the industry partners and what did they contribute?

The consortium included 2 industry partners (out of 11 total) and 1 SME. Based on the project description, industrial members provided diagnostic tools, treatment approaches, and advanced research tools. Specific company names are not included in the available dataset.

Consortium

Who built it

ECMED assembled 11 partners from 9 countries (BE, DE, ES, FI, FR, IT, NL, PL, UK), led by University College London. The consortium leans heavily academic, with 5 universities and 4 research organizations, while 2 industry partners (including 1 SME) provided diagnostic and research tools. The 18% industry ratio is typical for a training network rather than an industry-driven innovation project. For a business looking to access these results, the academic-heavy composition means strong published science but limited commercial packaging — you would likely need to invest in translating research outputs into products.

UNIVERSITY COLLEGE LONDONCoordinator · UK
DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EVparticipant · DE
UNIVERSITEIT ANTWERPENparticipant · BE
LEIBNIZ-INSTITUT FUER NEUROBIOLOGIEparticipant · DE
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIAparticipant · IT
AMSTERDAM UMC RESEARCH BVparticipant · NL
INSTYTUT BIOLOGII DOSWIADCZALNEJ IM. M. NENCKIEGO POLSKIEJ AKADEMII NAUKparticipant · PL
UNIVERSITE D'AIX MARSEILLEparticipant · FR
ITA-SUOMEN YLIOPISTOparticipant · FI
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAMparticipant · NL

How to reach the team

University College London, UK — use SciTransfer's coordinator lookup service to find the project lead's contact details

Order a report on this consortium See UNIVERSITY COLLEGE LONDON profile →

Next steps

Talk to the team behind this work.

Want to explore licensing the MEA seizure analysis protocol or connecting with ECMED researchers? SciTransfer can broker an introduction and help you evaluate commercial potential.

Order a report on this topic More in Health & Biomedical